Literature DB >> 8898750

Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease.

M L Kennard1, H Feldman, T Yamada, W A Jefferies.   

Abstract

Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age. A biochemical marker for monitoring the onset and progression of the disease would be a valuable tool for disease management. In addition, such a marker might be used as an end point in clinical intervention protocols. Here we provide evidence that the soluble form of the iron binding protein p97 is found in elevated amounts in the serum of Alzheimer's patients compared with healthy controls. This biochemical marker has the potential for identifying subjects afflicted with the disease and possibly for monitoring the onset and longitudinal progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898750     DOI: 10.1038/nm1196-1230

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  13 in total

1.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.

Authors:  M A Smith; P L Harris; L M Sayre; G Perry
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

3.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 4.  Causes of Alzheimer's disease.

Authors:  D G Munoz; H Feldman
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

Review 5.  Transferrin and transferrin receptor function in brain barrier systems.

Authors:  T Moos; E H Morgan
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

6.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

7.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

8.  Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease.

Authors:  Richard R Desrosiers; Yanick Bertrand; Quynh-Tran Nguyen; Michel Demeule; Reinhard Gabathuler; Malcolm L Kennard; Serge Gauthier; Richard Béliveau
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

9.  A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier.

Authors:  Delara Karkan; Cheryl Pfeifer; Timothy Z Vitalis; Gavin Arthur; Maki Ujiie; Qingqi Chen; Sam Tsai; Gerrasimo Koliatis; Reinhard Gabathuler; Wilfred A Jefferies
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

Review 10.  Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.

Authors:  Alison L Baird; Sarah Westwood; Simon Lovestone
Journal:  Front Neurol       Date:  2015-11-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.